taranabant

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Smoking

Conditions

Smoking

Trial Timeline

Jan 1, 2005 → Jun 1, 2005

NCT ID

NCT00109135

About taranabant

taranabant is a phase 2 stage product being developed by Merck for Smoking. The current trial status is completed. This product is registered under clinical trial identifier NCT00109135. Target conditions include Smoking.

What happened to similar drugs?

17 of 20 similar drugs in Smoking were approved

Approved (17) Terminated (0) Active (3)

✅Nicotine patch, nicotine inhaler, bupropion + Nicotine patchJohnson & JohnsonApproved

✅varenicline + placeboPfizerApproved

✅placebo + vareniclinePfizerApproved

✅Varenicline + PlaceboPfizerApproved

✅varenicline + vareniclinePfizerApproved

✅Varenicline Tartrate + PlaceboPfizerApproved

✅placebo + varenicline tartrate + bupropion hydrochloride + Nicotine Replacement Therapy PatchPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00131430	Phase 2/3	Completed	Aug 1, 2005	May 1, 2007	Obesity and Obesity-related Medical Conditions
NCT00109135	Phase 2	Completed	Jan 1, 2005	Jun 1, 2005	Smoking

Competing Products

20 competing products in Smoking

See all competitors

Product	Company	Stage	Hype Score
Brenipatide + Placebo	Eli Lilly	Phase 2	42
Nicotine + Nicotine + Nicotine	Johnson & Johnson	Phase 2	35
Nicotine replacement therapy + Nicotine replacement therapy	Johnson & Johnson	Phase 2	35
Nicotine Patch + Placebo Patch	Johnson & Johnson	Phase 1	29
Nicotine Patch + Placebo Patch + SLS Comparator Patch	Johnson & Johnson	Phase 1	29
Nicotine + Placebo	Johnson & Johnson	Pre-clinical	26
Nicotine Patch + Nicotine Patch Comparator + Placebo Patch	Johnson & Johnson	Phase 1	29
Nicotine Patch + Placebo Patch + No Patch Control	Johnson & Johnson	Phase 1	29
Nicotine gum + Placebo gum + Nicotine inhaler + Placebo inhaler	Johnson & Johnson	Phase 3	40
Nicotine patch, nicotine inhaler, bupropion + Nicotine patch	Johnson & Johnson	Approved	43
AZD4041 + Placebo	AstraZeneca	Phase 1	29
Nicotine replacement therapy	Novartis	Pre-clinical	22
AFQ065	Novartis	Phase 1	29
Liraglutide + Placebo	Novo Nordisk	Phase 2	35
Varenicline	Pfizer	Phase 2	35
placebo + Varenicline Tartarate	Pfizer	Phase 3	40
varenicline + placebo	Pfizer	Approved	39
varenicline (CP-526,555)	Pfizer	Phase 3	40
placebo + varenicline	Pfizer	Approved	43
Varenicline + Bupropion	Pfizer	Phase 3	40